Managed Care
Disease
Management

Overview of the LUME-lung 1, Phase 3 Trial

Martin Reck, MD, PhD, says that combination treatment with nintendanib was significantly superior to docetaxel monotherapy in non-small-cell lung cancer after one chemotherapy regimen (LUME-lung 1, Phase 3).

Meetings

HealthIMPACT Southeast Tampa, FL January 23, 2015